D.E. Shaw & Co
CUE icon

D.E. Shaw & Co’s Cue Biopharma CUE Stock Holding History

D.E. Shaw & Co’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,223
Closed -$134K – 4295
2023
Q2 		$134K Buy
+1,223
New +$144K ﹤0.01% 3802
2020
Q1 		– Sell
-430
Closed -$205K – 3979
2019
Q4 		$205K Buy
+430
New +$135K ﹤0.01% 3788

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's CUE Position: Q3 2023 in Review

D.E. Shaw & Co sold out of Cue Biopharma (CUE) in Q3 2023, closing a stake of 1,223 shares — an estimated $134K sold.

D.E. Shaw & Co first reported a position in CUE in Q4 2019 and held it in 2 quarters. The position peaked at $205K in Q4 2019. 75 funds tracked by Wall St. Rank hold CUE as of Q3 2023.

  • D.E. Shaw & Co reported no remaining Cue Biopharma position as of Q3 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,223 Cue Biopharma shares in Q3 2023, an estimated $134K.
  • D.E. Shaw & Co first reported a position in Cue Biopharma in Q4 2019 and held it in 2 quarters.
  • D.E. Shaw & Co's Cue Biopharma position peaked at $205K in Q4 2019.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2023.

Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.